[Hopespringpcsg] FW: Survey on Zytiga for pCODR

[Glen Tolhurst]

Hi all:

See survey below.

Participate if you wish.

Take care,

Glen

 

CCSN has launched a survey for a new medication for metastatic
castration-resistant prostate cancer called Zytiga (abiraterone acetate) to
prepare a submission the pan-Canadian Oncology Drug Review (pCODR).


This medication has been available in Canada since 2011 for patients with
metastatic castration-resistant prostate cancer in the post-chemotherapy
stages. Now, pCODR will consider its use in the pre-chemotherapy stage. As
you know, the pan-Canadian Oncology Drug Review invites patient groups like
CCSN to prepare and send in submissions so that patients and caregivers like
you can be heard. 

As a member of CCSN's Prostate Cancer Advisory Council, we are counting on
your help to spread the word about our survey. Over 30 advanced prostate
cancer patients and caregivers completed our previous survey, and we hope to
reach or surpass that number!

The survey can be accessed at https://www.surveymonkey.com/s/LN7K2BY and
will remain open until April 5, 2013.

Best,

Jackie


-- 

Jackie Manthorne

President and CEO

Présidente et chef de la direction

Canadian Cancer Survivor Network

Réseau canadien des survivants du cancer

1750 croissant Courtwood Crescent, Suite 111

Ottawa, ON K2C 2B5

Telephone / Téléphone : 613-898-1871

E-mail / Courriel : jmanthorne at survivornet.ca

Web site / site web: www.survivornet.ca

Blog: http://jackiemanthornescancerblog.blogspot.com/

Twitter: @survivornet.ca

-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://artsservices.uwaterloo.ca/pipermail/hopespringpcsg/attachments/20130322/05f5f406/attachment.html